UBXD1 is a recently identified adaptor for p97, a highly abundant and conserved member of the AAA family of ATPase that plays pivotal roles in a multitude of cellular processes involving the ubiquitin-proteasome pathway. Very little is known about the biochemical, cellular, and molecular functions of UBXD1. Here we report the generation of two mouse monoclonal antibodies, 5C3-1 and 2F8-24, that recognize UBXD1 using Western blotting, immunoprecipitation, and immunofluorescence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/hyb.2009.0035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation between skin cancer and therapy with anti-IL monoclonal antibodies in patients affected by moderate-to-severe psoriasis: an observational monocentric study.
Eur J Cancer Prev
January 2025
Department of Dermatology, University of Pisa.
Our study aimed to investigate the correlation between skin cancer and anti-interleukin (IL) therapy in patients with moderate-to-severe psoriasis. This was an observational monocentric study in which we enrolled a total of 235 patients in which 127 patients were affected by moderate-to-severe psoriasis and treated with anti-IL monoclonal antibodies (mAbs) for at least 6 months, whereas 108 patients affected by mild psoriasis were treated with topical therapies. Afterward, we performed a dermatologic visit to all the subjects, collecting anamnestic information including risk factors for skin cancer.
View Article and Find Full Text PDFBackground: This study aims at applying the AT(N) classification to a cohort of patients with Alzheimer's disease (AD) and related disorders, and to investigate how many cases would be eligible for the emerging disease-modifying treatments.
Method: We conducted a retrospective evaluation of 429 patients referred to the Memory Center of IRCCS San Raffaele Hospital in Milan. Patients underwent clinical/neuropsychological assessments, lumbar puncture, structural brain imaging, and positron emission tomography (FDG-PET).
Background: Alzheimer's disease (AD) is the most common cause of a decline in cognitive ability. The pathogenesis of AD involves the deposition of β-amyloid (Aβ) plaques and the formation of neurotoxic oligomers of Aβ protein. This leads to neurofibrillary tangles composed of phosphorylated Tau proteins, neuroinflammation, loss of nerve cells and synapses, and ultimately dementia.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Neurocognitive Unit, Division of Neurology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: Alzheimer's disease(AD) raises global concern with its impact on daily living. Anti-amyloid monoclonal antibodies (mAb) serving as specific treatments used in mild cognitive impairment(MCI) and mild dementia due to AD. Severe cerebral small vessel disease(SVD) lesions such as microbleeds and white matter hyperintensities are listed as exclusions according to the recommendation for mAb treatment.
View Article and Find Full Text PDFBackground: Lecanemab, an anti-amyloid therapy for early Alzheimer's disease (AD), received full FDA approval in July 2023 and subsequent approval in Japan in September 2023. Public reaction on social media was mixed, reflecting opinions on its efficacy, safety, and cost. We aimed to evaluate public perception of lecanemab's approval on social media, aiming to inform future communications and development strategies for anti-amyloid treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!